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Background and aims: Males have greater cardiometabolic risk than females, though the reasons for this
are poorly understood. The aim of this study was to examine the association between common Y
chromosomal haplogroups and cardiometabolic risk during early life.
Methods: In a British birth cohort, we examined the association of Y chromosomal haplogroups with
trajectories of cardiometabolic risk factors from birth to 18 years and with carotid-femoral pulse wave
velocity, carotid intima media thickness and left ventricular mass index at age 18. Haplogroups were
grouped according to their phylogenetic relatedness into categories of R, I, E, J, G and all other hap-
logroups combined (T, Q, H, L, C, N and O). Risk factors included BMI, fat and lean mass, systolic blood
pressure (SBP), diastolic blood pressure, pulse rate, triglycerides, high density lipoprotein cholesterol
(HDL-c), non-HDL-c and c-reactive protein. Analyses were performed using multilevel models and linear
regression, as appropriate.
Results: Y chromosomal haplogroups were not associated with any cardiometabolic risk factors from
birth to 18 years. For example, at age 18, the difference in SBP comparing each haplogroup with hap-
logroup R was 0.39mmHg (95% Confidence Interval (CI): 0.75, 1.54) for haplogroup I, 2.56mmHg (95%
CI: 0.76, 5.89) for haplogroup E, 0.02mmHg (95% CI: 2.87, 2.83) for haplogroup J, 1.28mmHg (95%
CI: 4.70, 2.13) for haplogroup G and 2.75mmHg (95% CI: 6.38, 0.88) for all other haplogroups
combined.
Conclusions: Common Y chromosomal haplogroups are not associated with cardiometabolic risk factors
during childhood and adolescence or with subclinical cardiovascular measures at age 18.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Sex differences in cardiometabolic risk are well-established but
are poorly understood [1e3]. The remaining lifetime risk oflogy Unit at the University of
N, UK.
'Keeffe).
r B.V. This is an open access articlecardiovascular disease (CVD) at age 40 is two in three for males
compared with one in two for females [4]. Males also develop type
2 diabetes mellitus (T2DM) at younger ages and at lower levels of
adiposity than females [5,6]. Sex differences in lifestyle and hor-
mones are likely to contribute to sex differences in cardiometabolic
risk [7]. The sex chromosomes, including the male Y chromosome
may also play an important role in cardiometabolic disease. How-
ever, because only 3% of Y chromosomal ancestral genes have
survived genetic decay over time compared to the X chromosomeunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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diometabolic disease has often been overlooked. Furthermore, the
role of the Y chromosome has often been perceived as one limited
to sex determination and reproductive function despite evidence
that many genes on the Y chromosome are involved in other non-
reproductive biological processes, and hence may be important to
male health beyond reproduction [1,10,11]. In addition, due to the
complexities of including the sex chromosomes in genetic associ-
ation studies (including reduced power due to the use of sex-
specific analyses, poor genotyping accuracy on current genome-
wide arrays and quality control issues) [1], the Y chromosome is
often excluded from Genome Wide Association Studies (GWAS) to
simplify analyses. Thus, the association between the Y chromosome
and cardiometabolic disease risk in males across the life course
remains poorly understood.
Recently, the association of the Y chromosome with car-
diometabolic disease risk in males has been studied using Y chro-
mosomal haplogroups, which are stable lineages of the Y
chromosome derived by genotyping and mapping to branches of
the Y chromosome phylogenetic tree [12]. Three studies found no
evidence that common Y chromosomal haplogroups were associ-
ated with cardiometabolic risk factors or vascular outcomes in
European men [13e15] while others have found some evidence of
blood pressure differences between haplogroups [16] and a 50%
increased risk of coronary artery disease (CAD) in carriers of hap-
logroup I compared with haplogroup R [17]. However, the associ-
ation of common Y chromosomal haplogroups with
cardiometabolic risk factors in early life (which are known to track
into adulthood and are associated with later cardiovascular risk)
has not been examined [18e20]. Given that the underlying path-
ophysiological process of atherosclerosis is already beginning
during childhood [21,22], examining the association of common Y
chromosomal haplogroups with cardiometabolic risk factors in
early life, may provide important aetiological insights into the role
of the Y chromosome in cardiometabolic risk, before pharmaco-
logical treatment of risk factors can bias associations. In addition,
examining associations with risk factor change over time, may
provide insights into the mechanisms underlying the role of the Y
chromosome in cardiometabolic risk, if associations emerge during
critical periods of growth and development in early life (such as
puberty).
The objectives of this study were to examine the association
between common Y chromosomal haplogroups and car-
diometabolic risk factors during childhood and adolescence. To do
this, we examined the associations of common Y chromosomal
haplogroups (haplogroup R, haplogroup I, haplogroup E, hap-
logroup J, haplogroup G, and all other haplogroups combined
(haplogroups T, Q, H, L, C, N and O)) with trajectories of car-
diometabolic risk factors from birth to 18 years in a contemporary
prospective birth cohort study in the South West of England. These
included BMI (from 1 to 18 years); fat and lean mass (from 9 to 18
years); systolic blood pressure (SBP), diastolic blood pressure (DBP),
pulse rate and glucose (from 7 to 18 years); triglycerides, high
density lipoprotein cholesterol (HDL-c) and non-HDL-c (from birth
to 18 years); c-reactive protein (CRP) (from 9 to 18 years) and
measures of sub-clinical cardiovascular disease (carotid-femoral
pulse wave velocity (PWV), left ventricular mass index (LVMI) and
carotid intima media thickness (cIMT)) at age 18 years.
2. Materials and methods
2.1. Study participants
The Avon Longitudinal Study of Parents and Children (ALSPAC) is
a prospective birth cohort study in the SouthWest England. [23,24]Pregnant women resident in one of the three Bristol-based health
districts with an expected delivery date between April 1, 1991 and
December 31, 1992 were invited to participate. The study has been
described elsewhere in detail. [23,24] ALSPAC initially enrolled a
cohort of 14,451 pregnancies, from which 13,867 live births
occurred in 13,761 women. Follow-up has included parent and
child completed questionnaires, links to routine data and clinic
attendance. Research clinics were held when the participants were
approximately 7, 9, 10, 11, 13, 15 and 18 years old. Ethical approval
for the study was obtained from the ALSPAC Ethics and Law Com-
mittee and the Local Research Ethics Committees. The study web-
site contains details of all the data that is available through a fully
searchable data dictionary http://www.bristol.ac.uk/alspac/
researchers/access/ [25].
2.2. Data
2.2.1. Genotyping of the Y chromosome
Blood samples for DNA extraction were obtained from several
sources, including cord blood, whole blood, and mouthwash sam-
ples from children who did not wish to give blood. A standard
phenol-cholorform extraction method was used for DNA extraction
for all samples from long-term storage and a salting-out method
was used for samples stored at 20 C for less than one month. All
batches of DNA extractions include a control sample to monitor
recovery [26]. A total of 9,912 of the ALSPAC offspring participants
were genotyped using the Illumina HumanHap550 quad genome-
wide single nucleotide polymorphism (SNP) genotyping platform
by Sample Logistics and Genotyping Facilities at the Wellcome
Trust Sanger Institute and LabCorp (Laboratory Corporation of
America) using support from 23andMe. PLINK software (v1.07) was
used to carry out quality control (QC) measures [27]. For each in-
dividual, the resulting Y chromosomal genotypes (816 SNPs) were
then piped into the Y-Fitter (v0.2) software, which maps genotype
data to the Y chromosome phylogenetic tree built by Karafet et al
(available online at sourceforge.net/projects/yfitter) and their
respective Y chromosomal haplogroup was determined [28]. After
removal of individuals with ‘false’ haplogroup determinations (i.e.,
individuals who did not have enough SNPs to reliably determine
haplogroup), 5,080 individuals were available. SNPs with a minor
allele frequency (MAF) of <1% and call rate of <95% were removed.
The pseudo-autosomal SNPs (coded as chromosome 25) were
removed from the analysis using the PLINK software [27]. In-
dividuals were excluded from analysis based on having incorrect
gender assignments, minimal or excessive heterozygosity (<0.320
and >0.345 for the Sanger data and <0.310 and >0.330 for the
LabCorp data), disproportionate levels of individual missingness
(>3%), evidence of cryptic relatedness (>10% IBD) and being of non-
European ancestry (as detected by a multidimensional scaling
analysis seeded with HapMap 2 individuals). EIGENSTRAT analysis
revealed no additional obvious population stratification and
genome-wide analyses with other phenotypes indicated a low
lambda.
Individuals belonging to haplogroup R (predominantly R1b and
R1a) were clustered into a single group and used as the reference
group in this analysis. Individuals belonging to haplogroup I (pre-
dominantly I1 and I2), E (predominantly E1b), J (predominantly J2)
and G (predominantly G2) were also clustered together, each into
their own separate groups (I, E, J, and G). The remaining hap-
logroups were then grouped together due to their low prevalence
in our cohort, listed in order of frequency: (T, Q, H, L, C, N and O).
Supplementary Table 1 shows a detailed breakdown of the specific
haplogroups contributing to these categories for CRP (risk factor
with fewest individuals and repeated measures) and BMI (risk
factor with greatest number of individuals and repeatedmeasures).
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Length (before the age of 2 years), height (from the age of 2
years) and weight data from the age of 1 year for the participants
were obtained from several sources including health visitor re-
cords, questionnaires and clinics from birth to 18 years [29]. BMI
was calculated as weight (kg) divided by height squared (m2).
Whole body less head, and central fat and lean mass were derived
from whole body dual energy X-ray absorptiometry (DXA) scans
assessed 5 times at ages 9, 11, 13, 15, and 18 using a Lunar prodigy
narrow fan beam densitometer.
2.2.3. SBP, DBP and pulse rate
At each clinic (ages 7, 9, 10, 11, 12, 15 and 18), SBP, DBP and pulse
rate were measured at least twice each with the child sitting and at
rest with the arm supported, using a cuff size appropriate for the
child's upper arm circumference and a validated blood pressure
monitor. The mean of the two final measures was used.
2.2.4. Blood based biomarkers of cardiometabolic risk
Non-fasting glucose was also measured at age 7 as part of
metabolomics assays, using Nuclear Magnetic Resonance (NMR)
Spectroscopy. In a random 10% of the cohort at age ~9 years, fasting
glucose was also available. Fasting glucose was available from
clinics held when participants were 15 and 18 years old. Tri-
glycerides, HDL-c and total cholesterol were measured in cord
blood at birth and from venous blood subsequently. Samples were
non-fasted at 7 and 9, with fasting measures available from clinics
at 15 and 18 years. Non-HDL-c was calculated by subtracting HDL-c
from total cholesterol at each measurement occasion. Trajectories
of glucose, triglycerides, HDL-c and non-HDL-c were derived from a
combination of measures from cord blood, fasting bloods, non-
fasting bloods and NMR spectroscopy.
2.2.5. Cardiovascular structure and function
Common carotid artery B-mode ultrasound images were ac-
quired with the head rotated to 45 from the midpoint using a
Zonare Z.OneUltra system equipped with a L10-5 linear transducer
(Zonare Medical Systems, CA, US). Images were recorded in Digital
Imaging and Communications in Medicine (DICOM) format as 10 s
cine-loop files for offline analysis using the Carotid Analyser
(Medical Imaging Applications, Coralville, IA). Left and right cIMT
were taken to be the average of 3 end-diastolic measurements of
the far-wall of the common carotid artery over a 5e10mm length,
10mm proximal to the bifurcation. The mean of left and right cIMT
was calculated and used in analyses.
A sub-sample of study participants from the 18-year clinic un-
derwent echocardiography using a HDI 5000 ultrasound machine
(Phillips) and P4-2 Phased Array ultrasound transducer using a
standard examination protocol. Left ventricular mass (LVM) was
estimated according to American Society of Echocardiography
(ASE) guidelines [30]. LVM measured at each age was indexed to
height2.7 (LVMI).
Aortic stiffness (PWV) was assessed using a Vicorder device
(Skidmore Medical, UK). Participants rested supine on a couch with
their head raised to 30. Real-time pulse-wave formswere recorded
simultaneously from proximal (right carotid) and distal (the upper
right thigh) sensor cuffs and the time delay measured. Transit
distance was measured from suprasternal notch directly to the top
of the thigh cuff. Measurements were taken until pressure wave-
forms over the carotid and thigh area were of high quality and
reproducible. Three PWV measurements, within 0.5m/s of each
other, were averaged.
Fig. 1 shows a flow diagram for the study and further details of
measurement of risk factors are available in Appendix 1 of the
Supplementary Material.2.3. Statistical analysis
2.3.1. Main analysis
We used multilevel models to examine the association between
common Y chromosomal haplogroups and change in each risk
factor across childhood and into adolescence [31,32]. Associations
between haplogroups and risk factors measured at one time point
only (PWV, cIMT, LVMI) were examined using linear regression.
Multilevel models estimate mean trajectories of the risk factor
while accounting for the non-independence (i.e. clustering) of
repeated measurements within individuals, change in scale and
variance of measures over time, and differences in the number and
timing of measurements between individuals (using all available
data from all eligible participants under a missing at-random
assumption (MAR)) [33,34]. Linear splines, fractional polynomials
and linear age terms were used in the modelling of trajectories.
Linear splines allow knot points to be fitted at different ages to
derive periods of change that are approximately linear. Fractional
polynomials involve raising age to many combinations of powers,
resulting in a wide range of possible curves and offering more
flexibility than standard polynomial approaches.
We included all participants with at least one measure of the
risk factor in each multilevel model, under a MAR assumption, to
minimise selection bias. All trajectories except BMI and CRP (fat
mass, lean mass, SBP, DBP, pulse rate, glucose, triglycerides, HDL-c
and non-HDL-c) were estimated using linear spline multilevel
models (with two levels: measurement occasion and individual).
The optimal linear splinemodel for each cardiometabolic risk factor
was selected based on previous work [33,35,36] or by comparing
model fit statistics (Akaike's Information Criterion [37]) for several
models with different knot points (placed at whole years closest to
mean age at clinics due to a greater density of measures). Trajec-
tories of BMI were modelled using fractional polynomials [38] with
two levels (measurement occasion and individual), since change in
BMI during childhood follows a complex pattern that cannot be
appropriately modelled using linear splines. CRP was modelled
using a linear age termwith two levels (measurement occasion and
individual). Model fit statistics for each risk factor trajectory are
shown in Supplementary Tables 4 to 12. An interaction between
haplogroups and each spline (in the case of linear spline multilevel
models) or the fractional polynomial age terms or linear age terms
(in the case of BMI or CRP) were included in the models to estimate
the difference in intercepts and slopes of each cardiometabolic risk
factor between the haplogroups. To allow BMI and CRP differences
between haplogroups over time to be more easily interpreted, co-
efficients from themodels were used to predict mean BMI or CRP at
different ages. All trajectories were modelled in MLwiN version
2.36 [39], called from Stata version 14 [40] using the runmlwin
command. [41].
In all models, age (in years) was centred at the first available
measure. Values of cardiometabolic risk factors that had a skewed
distribution (BMI, fat mass, triglycerides and CRP) were (natural)
log transformed prior to analyses. Graphs displayed for these risk
factors are in original units and derived by back transforming from
the natural log scale. Differences and confidence intervals were
calculated on the log-scale, which were also back-transformed and
are therefore interpreted as the ratio of geometric means. We
performed power calculations for risk factors with the smallest
sample sizes for both i) the group with the smallest number of
participants (haplogroup G) and the group of greatest clinical in-
terest in the analysis (Haplogroup I due to its previous association
with a 50% increased risk of CAD [17]). Further details of model
selection and power calculations are provided in Appendix 2 and
Supplementary Tables 2 and 3. Model fit statistics for each risk
factor trajectory are shown in Supplementary Tables 4-12.
Fig. 1. Flow diagram of study.
BMI, body mass index; BP, blood pressure; cIMT, carotid intima media thickness; CRP, c-reactive protein; LVMI, left ventricular mass index; PWV, pulse wave velocity. a Lipids include
triglyceride, high density lipoprotein cholesterol (HDL-c) and non-HDL-c.
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We performed sensitivity analyses excluding all observations of
lipids and glucose, for participants who reported eating in the
4 hours preceding the 15 and 18-year clinics to examine if our re-
sults were altered by the inclusion of some non-fasted bloods at
these clinics. We performed sensitivity analysis restricting BMI to
participants with greater than 6 measures, to examine if results
were driven by participants with a greater number of measures.3. Results
Table 1 shows the number of participants with available mea-
sures of cardiometabolic risk factors at each age along with the
median and interquartile range (IQR) of available measures. Sample
sizes for repeatedly measured risk factors ranged from 2,989 par-
ticipants (5,341 repeated measures) for CRP up to 4,693 partici-
pants (45,316 repeated measures) for BMI. Sample sizes formeasures of vascular structure and function measured at age 18
ranged from 704 to 1,523. Table 2 shows the frequency of each
haplogroup analysed in the study. Maternal marital status, house-
hold occupational social class, maternal and paternal education and
maternal smoking during pregnancy did not differ by offspring
haplogroup (Supplementary Table 13).
We found no strong evidence of a difference in the trajectories of
any of the cardiometabolic risk factors across childhood and
adolescence between haplogroups R, I, E, J, G and other hap-
logroups combined (Figs. 2e6 and Supplementary Tables 14e21).
We also found no strong evidence that haplogroups were associ-
ated with PWV, cIMT or LVMI at age 18 (Table 3). For example,
compared with haplogroup R, haplogroup J had similar log BMI at
age 1 year (difference:2.76% 95% Confidence Interval CI:12.96%,
7.45%) and the groups remained similar at age 18 years (difference:
2.72% (95% CI: 0.72%, 5.15%), as indicated by confidence intervals
that span the null value (Supplementary Table 14).
Table 1
Number of participants with cardiometabolic measures at each time point.




Range of measures Median measures
(IQR)
BMIa x x x x x x x x 4693 45,316 1e36 12 [9e16]
Fat/lean mass 3090 2942 2567 2153 1802 3624 12,554 1e5 4 [3e5]
SBP/DBP/pulse
rate
3417 3230 3012 2954 2800 2179 1740 3981 19,332 1e7 6 [5e7]
Glucose 2138 421 1555 1372 3060 5586 1e4 2 [1e3]
Lipidb 1707 2564 2417 1575 1399 4186 9662 1e4 2 [1e3]
CRP 2395 1561 1385 2989 5341 1e3 2 [1e3]
PWV e e e e e e e e e 1249 1249 1249 1 1
cIMT e e e e e e e e e 1523 1523 1523 1 1
LVMI e e e e e e e e e 704 704 704 1 1
cIMT, carotid intima media thickness; CRP, c-reactive protein; DBP, diastolic blood pressure; IQR, interquartile range; LVMI, left ventricular mass index; PWV, pulse wave
velocity; SBP, systolic blood pressure.
a Measures available at each of these approximate ages and at several ages in between, but exact timing and number of BMImeasures not shown as measures were available
from questionnaires, routine child health records and research clinics at different mean ages from 1 to 18 years.
b Lipids include triglyceride, high density lipoprotein cholesterol (HDL-c) and non-HDL-c.
Table 2
Frequencies of haplogroups among participants with at least 1 measure of each risk factor.
BMI Fat mass/Lean mass Blood pressure/pulse rate Glucose Lipids CRP PWV cIMT LVMI
Total 4667 3624 3981 3060 4186 2989 1247 1523 704
Ra 3, 384 (72.0) 2627 (72.5) 2870(72.1) 2206 (72.1) 3017 (72.1) 2165 (72.4) 924 (74.0) 1127 (74.00) 523 (74.3)
Ia 887 (18.9) 670 (18.5) 742 (18.6) 564 (18.4) 786 (18.8) 550 (18.4) 226 (18.1) 280 (18.4) 120 (17.0)
Ea 140 (3.0) 106 (2.9) 121 (3.0) 93 (3.0) 124 (3.0) 90 (3.0) 36 (2.9) 43 (2.8) 22 (3.1)
Ja 125 (2.7) 96 (2.7) 112 (2.8) 82 (2.7) 116 (2.8) 58 (1.9) 26 (2.1) 32 (2.1) 16 (2.3)
Ga 86 (1.8) 68 (1.9) 74 (1.9) 61 (2.0) 79 (1.9) 81 (2.7) 24 (1.9) 26 (1.7) 17 (2.4)
Otherb 45 (1.5) 57 (1.6) 62 (1.6) 54 (1.8) 64 (1.5) 45 (1.5) 13 (1.0) 15 (1.0) 6 (0.9)
cIMT, carotid intima media thickness; CRP, c-reactive protein; DBP, diastolic blood pressure; IQR, interquartile range; LVMI, left ventricular mass index; PWV, pulse wave
velocity; SBP, systolic blood pressure.
a For details of the specific subgroups contributing to these larger groups see Supplementary Table 1. Haplogroup R contains predominantly R1b and R1a, I contains
predominantly I2 and I1, E contains predominantly E1b, J contains predominantly J2 and G contains predominantly G2.
b The “other” haplogroup includes (listed in order of frequency): T, Q, H, L, C, N and O. Frequencies of these are also displayed in Supplementary Table 1.
Fig. 2. Mean predicted trajectories of anthropometry.
Mean predicted trajectories of (A) BMI (1e18 years), (B) height-adjusted fat mass and (C) height-adjusted lean mass (9e18 years) by haplogroup.
For details of the specific subgroups contributing to these larger groups see Supplementary Table 1. The “other” haplogroup includes (listed in order of frequency): T, Q, H, L, C, N and
O. Frequencies of these are also displayed in Supplementary Table 1. Confidence intervals for all haplogroups are displayed in grey but are entirely over-lapping as the difference
between the trajectories of the haplogroups spans the null value across the entire age range. Detailed results with confidence intervals are provided in Supplementary Tables 14e16.
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altered when the observations of participants who ate in the
4 hours before the 15-or 18-year clinics were excluded
(Supplementary Figs. 1 and 2). Results for BMI were not altered
when the analysis was restricted to participants with 6 or more
repeated measures of BMI (Supplementary Fig. 3).4. Discussion
4.1. Summary
Understanding the association of common Y chromosomal
haplogroups with cardiometabolic risk can provide insights into
Fig. 3. Mean predicted trajectories of blood pressure and pulse rate by haplogroup.
Mean predicted trajectories of (A) SBP, (B) DBP and (C) pulse rate from 7 to 18 years by haplogroup. DBP, diastolic blood pressure; SBP, systolic blood pressure. For details of the
specific subgroups contributing to these larger groups see Supplementary Table 1. The “other” haplogroup includes (listed in order of frequency): T, Q, H, L, C, N and O. Frequencies of
these are also displayed in Supplementary Table 1. Confidence intervals for all haplogroups are displayed in grey but are entirely over-lapping as the difference between the
trajectories of the haplogroups spans the null value across the entire age range. Detailed results with confidence intervals are provided in Supplementary Table 17.
Fig. 4. Mean predicted trajectories of glucose (7e18 years) by haplogroup.
For details of the specific subgroups contributing to these larger groups see Supplementary Table 1. The “other” haplogroup includes (listed in order of frequency): T, Q, H, L, C, N and
O. Frequencies of these are also displayed in Supplementary Table 1. Confidence intervals for all haplogroups are displayed in grey but are entirely over-lapping as the difference
between the trajectories of the haplogroups spans the null value across the entire age range. Detailed results with confidence intervals are provided in Supplementary Table 18.
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this study, we found no strong evidence that common Y chromo-
somal haplogroups were associated with cardiometabolic risk fac-
tors in males during childhood and adolescence, or with measures
of vascular structure and function at age 18. These findings suggest
that common variation on the Y chromosome is unlikely to play a
role in cardiometabolic risk in males or sex differences in car-
diometabolic risk factors which have been shown to exist in early
life in several other longitudinal cohorts such as the Bogalusa Heart
Study and Project Heartbeat! [42e44].
Our results are comparable with findings from previous studies
in adults [13e17]. Charchar and colleagues showed a 50% increased
risk of CAD in haplogroup I compared with haplogroup R among
3,233 Britishmen [17]. This association appeared to be independent
of conventional cardiovascular risk factors such as BMI, SBP andtriglycerides, which our findings support. In addition, Bloomer and
colleagues did not find strong evidence of an association between
haplogroup I compared with all other haplogroups and car-
diometabolic risk factors in 1,988 healthy young menwhile a Polish
study of men aged 20e79 years also found no strong evidence of an
association between common Y chromosomal haplogroups (hap-
logroups R, I, E, N, J, F) and cardiometabolic risk factors [13,15]. Our
findings are also in line with a recent Dutch case-control study of
males aged ~70 years which found no difference in Y chromosomal
haplogroup distribution (haplogroups R, I, E, G, J) between patients
undergoing vascular surgery comparedwith the general population
[14]. Our study replicates these previous findings but in a larger
cohort with repeated measures of risk factors across childhood and
adolescence.
Fig. 5. Mean predicted trajectories of lipids by haplogroup.
Mean predicted trajectories of (A) triglyceride, (B) HDL-c and (C) non-HDL-c from birth to 18 years by haplogroup.
HDL-c, high density lipoprotein cholesterol; non-HDL-c, non-high density lipoprotein cholesterol. For details of the specific subgroups contributing to these larger groups see
Supplementary Table 1. The “other” haplogroup includes (listed in order of frequency): T, Q, H, L, C, N and O. Frequencies of these are also displayed in Supplementary Table 1.
Confidence intervals for all haplogroups are displayed in grey but are entirely over-lapping as the difference between the trajectories of the haplogroups spans the null value across
the entire age range. Detailed results with confidence intervals are provided in Supplementary Tables 19 and 20.
Fig. 6. Mean predicted trajectories of CRP from 9 to 18 years by haplogroup.
CRP, c -reactive protein. For details of the specific subgroups contributing to these larger groups see Supplementary Table 1. The “other” haplogroup includes (listed in order of
frequency): T, Q, H, L, C, N and O. Frequencies of these are also displayed in Supplementary Table 1. Confidence intervals for all haplogroups are displayed in grey but are entirely
over-lapping as the difference between the trajectories of the haplogroups spans the null value across the entire age range. Detailed results with confidence intervals are provided in
Supplementary Table 21.
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chromosomal haplogroups with subclinical measures of vascular
disease such as PWV, cIMT and LVMI. Whilst we did not observe an
association between common Y chromosomal haplogroups and
PWV and cIMT, there was an indication that males in haplogroup I
had higher LVMI at age 18 years, though confidence intervals
spanned the null value. Further analyses of the association of
common Y chromosomal haplogroups with these subclinical
measures of atherosclerotic risk as this cohort matures may be
informative in understanding whether the association with LVMI
strengthens with age. Further analyses of these associations willalso be of interest as coverage of the Y chromosome in current
genotyping arrays improves, given that this is still limited, as
compared to coverage available for autosomes. In addition, to date,
most association studies of the Y chromosome have been per-
formed in single cohorts, which may be limited in statistical power.
Therefore, future association studies of the Y chromosome may
benefit from the use of meta-analysis, as has been applied to GWAS
of autosomes. This would permit estimates of Y chromosome as-
sociations to be combined across multiple studies, allowing for
increased power to detect genetic signals on the Y chromosome.
Table 3
Cardiovascular structure and function at age 18 by haplogroup.
Risk factor N Predicted risk factor at age 18 Estimate (95% CI)
Log carotid-femoral PWV (m/s) 1249
Ra 1.79 (1.78, 1.80) reference
Ia 1.79 (1.78, 1.80) 0.00005 (0.02, 0.02)
Ea 1.78 (1.74, 1.81) 0.01 (0.05, 0.02)
Ja 1.79 (1.75, 1.84) 0.005 (0.04, 0.05)
Ga 1.79 (1.75, 1.84) 0.004 (0.04, 0.05)
Otherb 1.77 (1.71, 1.83) 0.02 (0.08, 0.04)
Mean cIMT (mm) 1523
Ra 0.48 (0.48, 0.49) reference
Ia 0.48 (0.48, 0.49) 0.002 (0.01, 0.003)
Ea 0.48 (0.47, 0.49) 0.005 (0.019, 0.009)
Ja 0.49 (0.47, 0.50) 0.005 (0.011, 0.021)
Ga 0.48 (0.47, 0.50) 0.0002 (0.018, 0.018)
Otherb 0.48 (0.46, 0.51) 0.001 (0.022, 0.024)
LVMI (g/m2.7) 704
Ra 29.95 (29.40, 30.49) reference
Ia 31.13 (29.99, 32.27) 1.18 (0.08, 2.45)
Ea 28.99 (26.33, 31.66) 0.96 (3.68, 1.76)
Ja 30.02 (26.90, 33.15) 0.07 (3.10, 3.25)
Ga 30.53 (27.49, 33.56) 0.58 (2.50, 3.66)
Otherb 33.20 (28.10, 38.30) 3.25 (1.88, 8.38)
CI, confidence interval; cIMT; carotid intima media thickness, LVMI; Left ventricular mass index, PWV; Pulse wave velocity.
a For details of the specific subgroups contributing to these larger groups see Supplementary Table 1.
b The “other” haplogroup includes (listed in order of frequency): T, Q, H, L, C, N and O. Frequencies of these are also displayed in Supplementary Table 1.
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There are several strengths to our study, including its prospec-
tive design, availability of repeated measures over time, the ability
to examine a range of cardiometabolic risk factors, and the use of
multi-level models which take account of clustering of repeated
measures within individuals and the correlation betweenmeasures
over time. Our study is the first to examine the association of
common Y chromosomal haplogroups with change over time in
cardiometabolic risk factors during childhood and adolescence and
with measures of sub-clinical cardiovascular disease. In addition,
we have been able to perform subgroup analyses examining hap-
logroups not investigated in previous analyses such as haplogroups
E, J and G. Examining cardiometabolic risk factors during childhood
and adolescence reduces the possibility that null associations be-
tween common Y chromosomal haplogroups and risk factors are
affected by pharmacological treatment, which may attenuate as-
sociations in adults. Limitations include combining non-fasting and
fasting bloods for risk factors, the availability of measures from
birth for only 3 out of the 10 repeatedly measured risk factors, and
the inclusion of glucose from NMR spectroscopy at age 7. We
acknowledge that assays in cord-blood may not be directly com-
parable to those measured in serum or plasma later in life.
Furthermore, with a period of 9 or more years after the cord blood
measures before the next measure of triglycerides, HDL-c and non-
HDL-c, there is a strong assumption that these cardiometabolic risk
factors change in a linear fashion between birth and age nine. The
number of people with measurements of each cardiometabolic risk
factor varied, meaning that our analysis samples differed between
each cardiometabolic risk factor and were not directly comparable.
Loss to follow-up is also a limitation, which may have introduced
selection bias. However, we have aimed to minimise potential bias
by including all participants with at least a single measure of each
risk factor. We have also only been able to examine associations of
common Y chromosomal haplogroups with cardiometabolic risk
factors in a single study and have not been able to replicate our
findings. Therefore, replication of our results in a cohort of similar
design is essential to validate our findings. Given that haplogroup Iwas previously associatedwith a 50% increased risk of CAD [17], our
power calculation showing that we had 80% power to detect at least
a difference of 0.2 standard deviations in LVMI between haplogroup
I and haplogroup R demonstrates that our analysis is likely to have
been sufficient to detect a true difference if one existed. In contrast,
as we only had statistical power to detect a difference of 0.6 stan-
dard deviations in LVMI for the least common haplogroup (hap-
logroup G), our analysis may be underpowered to detect smaller
effect sizes for this group and our findings require replication in
cohorts with greater sample sizes to confirm our findings. In
addition, the “other” haplogroups combined category was formed
by combining haplogroups for which sample sizes were too small to
analyse individually in our study. Therefore, the groups were not
analysed together due to phylogenetic relatedness as with cate-
gories, R, I, E, J, and G and the results for this haplogroup should be
interpreted with caution both due to its heterogeneity and small
sample size. We have not adjusted for multiple testing given that
our outcomes are not independent of each other and that our
overall conclusion that common Y chromosomal haplogroups are
not associated with trajectories of cardiometabolic risk in early life
would not be altered by doing so. Finally, it is possible that we have
not found evidence of an association of common Y chromosomal
haplogroups with cardiometabolic measures and vascular out-
comes during childhood and adolescence because differences be-
tween haplogroups may not become apparent until later in life.
Nevertheless, our findings demonstrate that, if haplogroups are
associated with cardiometabolic risk in later life, their impact on
risk factors or vascular measures is not already evident before the
end of adolescence, when the early origins of atherosclerotic orig-
inate [18e20].4.3. Conclusion
We found no strong evidence that common Y chromosomal
haplogroups are associated with cardiometabolic risk factors in
males during childhood and adolescence or with measures of
vascular structure and function at age 18.
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